{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:49:29Z","timestamp":1788173369921,"version":"build-2803163510"},"reference-count":56,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/ehjci\/jey132","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T03:30:28Z","timestamp":1535081428000},"source":"Crossref","is-referenced-by-count":8,"title":["Multimodality imaging in Fabry cardiomyopathy: from early diagnosis to therapeutic targets"],"prefix":"10.1093","author":[{"given":"Sebastian","family":"Militaru","sequence":"first","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases \u201cProf. Dr. C. C. Iliescu\u201d, Bucharest, Romania"},{"name":"University of Medicine and Pharmacy, Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Ginghin\u0103","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases \u201cProf. Dr. C. C. Iliescu\u201d, Bucharest, Romania"},{"name":"University of Medicine and Pharmacy\u201cCarol Davila\u201d, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan A","family":"Popescu","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases \u201cProf. Dr. C. C. Iliescu\u201d, Bucharest, Romania"},{"name":"University of Medicine and Pharmacy\u201cCarol Davila\u201d, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"S\u0103ftoiu","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy, Craiova, Romania"},{"name":"Emergency County Hospital, Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Linhart","sequence":"additional","affiliation":[{"name":"2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxandra","family":"Jurcu\u0163","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases \u201cProf. Dr. C. C. Iliescu\u201d, Bucharest, Romania"},{"name":"University of Medicine and Pharmacy\u201cCarol Davila\u201d, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"key":"key\n\t\t\t\t20180921023153_jey132-B1","volume-title":"Natural History of Fabry Disease [Internet]","author":"Mehta","year":"2006"},{"key":"key\n\t\t\t\t20180921023153_jey132-B2","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180921023153_jey132-B3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20180921023153_jey132-B4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin Genet"},{"key":"key\n\t\t\t\t20180921023153_jey132-B5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/190372a0","article-title":"Gene action in the X-chromosome of the mouse (Mus musculus L.)","volume":"190","author":"Lyon","year":"1961","journal-title":"Nature"},{"key":"key\n\t\t\t\t20180921023153_jey132-B6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J Med Genet"},{"key":"key\n\t\t\t\t20180921023153_jey132-B7","doi-asserted-by":"crossref","first-page":"30.","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"key\n\t\t\t\t20180921023153_jey132-B8","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/hrt.2005.063818","article-title":"The heart in Anderson-Fabry disease and other lysosomal storage disorders","volume":"93","author":"Linhart","year":"2007","journal-title":"Heart"},{"key":"key\n\t\t\t\t20180921023153_jey132-B9","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/eurheartj\/ehp588","article-title":"Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity","volume":"31","author":"Wu","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180921023153_jey132-B10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jcmg.2015.11.002","article-title":"T1 mapping by CMR imaging: from histological validation to clinical implication","volume":"9","author":"Kammerlander","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"key\n\t\t\t\t20180921023153_jey132-B11","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","article-title":"Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy","volume":"110","author":"Chimenti","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180921023153_jey132-B12","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180921023153_jey132-B13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10545-013-9659-2","article-title":"Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS)","volume":"37","author":"Palecek","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"key\n\t\t\t\t20180921023153_jey132-B14","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease Survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"key":"key\n\t\t\t\t20180921023153_jey132-B15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","article-title":"Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995\u20132017","volume":"55","author":"Doheny","year":"2018","journal-title":"J Med Genet"},{"key":"key\n\t\t\t\t20180921023153_jey132-B16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180921023153_jey132-B17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry\u2019s cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180921023153_jey132-B18","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease","volume":"114","author":"Kr\u00e4mer","year":"2014","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180921023153_jey132-B19","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet"},{"key":"key\n\t\t\t\t20180921023153_jey132-B20","first-page":"2733","article-title":"ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180921023153_jey132-B21","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1136\/hrt.2010.204586","article-title":"The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy","volume":"96","author":"Niemann","year":"2010","journal-title":"Heart"},{"key":"key\n\t\t\t\t20180921023153_jey132-B22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.echo.2016.11.014","article-title":"Right ventricular hypertrophy, systolic function, and disease severity in Anderson-Fabry disease: an echocardiographic study","volume":"30","author":"Graziani","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"key":"key\n\t\t\t\t20180921023153_jey132-B23","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.echo.2008.09.002","article-title":"Right ventricular involvement in Fabry disease","volume":"21","author":"Palecek","year":"2008","journal-title":"J Am Soc Echocardiogr"},{"key":"key\n\t\t\t\t20180921023153_jey132-B24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ultrasmedbio.2010.10.017","article-title":"Prominent papillary muscles in Fabry disease: a diagnostic marker?","volume":"37","author":"Niemann","year":"2011","journal-title":"Ultrasound Med Biol"},{"key":"key\n\t\t\t\t20180921023153_jey132-B25","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","article-title":"Early detection of Fabry cardiomyopathy by tissue Doppler imaging","volume":"107","author":"Pieroni","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180921023153_jey132-B26","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/eurheartj\/eht098","article-title":"Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease","volume":"34","author":"Kr\u00e4mer","year":"2013","journal-title":"Eur Hear J"},{"key":"key\n\t\t\t\t20180921023153_jey132-B27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijcard.2008.04.075","article-title":"Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy","volume":"132","author":"Toro","year":"2009","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20180921023153_jey132-B28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10545-013-9607-1","article-title":"Early cardiovascular remodelling in Fabry disease","volume":"37","author":"Costanzo","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"key\n\t\t\t\t20180921023153_jey132-B29","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180921023153_jey132-B30","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1093\/eurheartj\/ehm454","article-title":"A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium","volume":"28","author":"Weidemann","year":"2007","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180921023153_jey132-B31","doi-asserted-by":"crossref","DOI":"10.1111\/echo.13496","article-title":"Loss of base-to-apex circumferential strain gradient: a specific pattern of Fabry cardiomyopathy?","author":"Labombarda","year":"2017","journal-title":"Echocardiography"},{"key":"key\n\t\t\t\t20180921023153_jey132-B32","doi-asserted-by":"crossref","first-page":"36.","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"key\n\t\t\t\t20180921023153_jey132-B33","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.lpm.2007.01.006","article-title":"Maladie de Fabry: propositions d\u2019ungroupe d\u2019experts fran\u00e7ais concernant le diagnostic, le traitement et le suivi des patients","volume":"36","author":"Lidove","year":"2007","journal-title":"Presse Med"},{"key":"key\n\t\t\t\t20180921023153_jey132-B34","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/eurheartj\/ehs166","article-title":"Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis","volume":"34","author":"Yousef","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180921023153_jey132-B35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/14017431.2017.1332383","article-title":"Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study","volume":"51","author":"Madsen","year":"2017","journal-title":"Scand Cardiovasc J"},{"key":"key\n\t\t\t\t20180921023153_jey132-B36","doi-asserted-by":"crossref","first-page":"1034.","DOI":"10.1093\/ehjci\/jew187","article-title":"Insight into hypertrophied hearts: a cardiovascular magnetic resonance study of papillary muscle mass and T1 mapping","volume":"18","author":"Kozor","year":"2017","journal-title":"Eur Hear J \u2013 Cardiovasc Imaging"},{"key":"key\n\t\t\t\t20180921023153_jey132-B37","doi-asserted-by":"crossref","first-page":"92.","DOI":"10.1186\/1532-429X-15-92","article-title":"Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement","volume":"15","author":"Moon","year":"2013","journal-title":"J Cardiovasc Magn Reson"},{"key":"key\n\t\t\t\t20180921023153_jey132-B38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1161\/CIRCRESAHA.116.307974","article-title":"T1 mapping in characterizing myocardial disease: a comprehensive review","volume":"119","author":"Puntmann","year":"2016","journal-title":"Circ Res"},{"key":"key\n\t\t\t\t20180921023153_jey132-B39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/CIRCIMAGING.113.000482","article-title":"Mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex","volume":"6","author":"Thompson","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"key\n\t\t\t\t20180921023153_jey132-B40","doi-asserted-by":"crossref","first-page":"99.","DOI":"10.1186\/s12968-014-0099-4","article-title":"Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance","volume":"16","author":"Pica","year":"2014","journal-title":"J Cardiovasc Magn Reson"},{"key":"key\n\t\t\t\t20180921023153_jey132-B41","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jacc.2016.07.741","article-title":"Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy","volume":"68","author":"Nordin","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180921023153_jey132-B42","doi-asserted-by":"crossref","first-page":"Q43.","DOI":"10.1186\/1532-429X-18-S1-Q43","article-title":"Native T1 mapping versus CMR feature tracking (FT) derived strain analysis for the assessment of cardiac disease manifestation in Anderson Fabry","volume":"18","author":"Reid","year":"2016","journal-title":"J Cardiovasc Magn Reson"},{"key":"key\n\t\t\t\t20180921023153_jey132-B43","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1177\/0284185116675657","article-title":"Segment-by-segment assessment of left ventricular myocardial affection in Anderson-Fabry disease by non-enhanced T1-mapping","volume":"58","author":"Walter","year":"2017","journal-title":"Acta Radiol"},{"key":"key\n\t\t\t\t20180921023153_jey132-B44","doi-asserted-by":"crossref","first-page":"1461.","DOI":"10.1093\/eurheartj\/ehi258","article-title":"Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies","volume":"26","author":"Mahrholdt","year":"2005","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180921023153_jey132-B45","doi-asserted-by":"crossref","first-page":"14.","DOI":"10.1186\/s12968-016-0233-6","article-title":"Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease","volume":"18","author":"Deva","year":"2016","journal-title":"J Cardiovasc Magn Reson"},{"key":"key\n\t\t\t\t20180921023153_jey132-B46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijcard.2011.03.023","article-title":"MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry disease","volume":"160","author":"Koeppe","year":"2012","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20180921023153_jey132-B47","article-title":"Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice","author":"Baig","year":"2017","journal-title":"Europace"},{"key":"key\n\t\t\t\t20180921023153_jey132-B48","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007168","article-title":"Proposed stages of myocardial phenotype development in Fabry disease","author":"Nordin","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"key\n\t\t\t\t20180921023153_jey132-B49","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"key\n\t\t\t\t20180921023153_jey132-B50","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1253\/circj.CJ-16-0690","article-title":"Focal reduction in cardiac 123I-metaiodobenzylguanidine uptake in patients with Anderson-Fabry disease","volume":"80","author":"Yamamoto","year":"2016","journal-title":"Circ J"},{"key":"key\n\t\t\t\t20180921023153_jey132-B51","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1007\/s00259-017-3778-1","article-title":"Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease","volume":"44","author":"Imbriaco","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"key\n\t\t\t\t20180921023153_jey132-B52","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10545-005-0563-2","article-title":"Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease","volume":"28","author":"Kalliokoski","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"key\n\t\t\t\t20180921023153_jey132-B53","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","article-title":"The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"key\n\t\t\t\t20180921023153_jey132-B54","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/eurjhf\/hft104","article-title":"Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease","volume":"15","author":"Tomberli","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20180921023153_jey132-B55","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00259-015-3036-3","article-title":"First experience of simultaneous PET\/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease","volume":"42","author":"Nappi","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"key\n\t\t\t\t20180921023153_jey132-B56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in Fabry disease","author":"Wanner","year":"2018","journal-title":"Mol Genet Metab"}],"container-title":["European Heart Journal - Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcimaging\/advance-article-pdf\/doi\/10.1093\/ehjci\/jey132\/25817668\/jey132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T21:45:39Z","timestamp":1571780739000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/advance-article\/doi\/10.1093\/ehjci\/jey132\/5104794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":56,"URL":"https:\/\/doi.org\/10.1093\/ehjci\/jey132","relation":{},"ISSN":["2047-2404","2047-2412"],"issn-type":[{"value":"2047-2404","type":"print"},{"value":"2047-2412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]}}}